Papers of note in Science Translational Medicine

ImmunodeficiencySAPping immunopathologyDGKα inhibition restores apoptosis in SAP-deficient lymphocytes, decreasing immunopathology in XLP-1 patients.E. Ruffo, V. Malacarne, S. E. Larsen, R. Das, L. Patrussi, C. Wülfing, C. Biskup, S. M. Kapnick, K. Verbist, P. Tedrick, P. L. Schwartzberg, C. T. Baldari, I. Rubio, K. E. Nichols, A. L. Snow, G. Baldanzi, A. Graziani, Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1. Sci. Transl. Med.8, 321ra7 (2016). [Abstract]AllergyFighting food allergyInfants who develop food allergy display hyperresponsive innate immunity at birth that promotes nonclassical TH2 differentiation.Y. Zhang, F. Collier, G. Naselli, R. Saffery, M. L. K. Tang, K. J. Allan, A.-L. Ponsonby, L. C. Harrison, P. Vuillermin, on behalf of the BIS Investigator Group, Cord blood monocyte–derived inflammatory cytokines suppress IL-2 and induce nonclassic “TH2-type” immunity associated with development of food allergy. Sci. Transl. Med.8, 321ra8 (2016). [Abstract]Fragile X SyndromeThe mGluR theory of fragile X, put to the testIn contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.E. Berry-Kravis, V. Des Portes, R. Hagerman, S. Jacquemont, P. Charles, J. Visootsak, M. Brinkman, K. Rerat, B. Koumaras, L. Zhu, G. M. Barth, T. Jaecklin, G. Apostol, F. von Raison, Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med.8, 321ra5 (2016). [Abstract]S. S. Jeste, D. H. Geschwind, Clinical trials for neurodevelopmental disorders: At a therapeutic frontier. Sci. Transl. Med.8, 321fs1 (2016). [Abstract]